ASXReplacement Target Market Determination
capital_raise announcement
CYP
Pharmaceuticals, Biotechnology & Life Sciences
Cynata Therapeutics
- Short interest
- 0.00%
- −0.62 pp 30d
- as of 13 May 2026
- Reported shorts
- 3.1K
- Shares on issue
- 243.454M
Cynata Therapeutics (CYP) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Entitlement Offer & Unmarketable Parcel Sale Facility
capital_raise announcement
Termination of At-the-Market Subscription Deed
other announcement
Cynata Receives R&D TI Refund & Repays R&D TI Loan
other announcement
Google NewsWhat Did Cynata Therapeutics (ASX:CYP) Report for FY2026 After Two Clinical Trials Missed Their Targets? - kalkine.com.au
What Did Cynata Therapeutics (ASX:CYP) Report for FY2026 After Two Clinical Trials Missed Their Targets? kalkine.com.au
R&D Tax Incentive Loan Facility Extension
other announcement
Date of AGM and Closing Date for Director Nominations
other announcement
Notification under Listing Rule 4.3D
other announcement
Notification of cessation of securities - CYP
other announcement
Appendix 4E & Preliminary Final Report
other announcement
Cynata Therapeutics (ASX:CYP) Shares Slide to a New 52-Week Low - Kalkine
Cynata Therapeutics (ASX:CYP) Shares Slide to a New 52-Week Low Kalkine
June 2026 Quarterly Activity Report & Appendix 4C
other announcement
Board, Management Changes, Expenditure Reductions, RDTI Loan
other announcement
Cynata Therapeutics (ASX:CYP): Is This Regenerative Medicine Stock Ready for a Re-Rating? - Kalkine
Cynata Therapeutics (ASX:CYP): Is This Regenerative Medicine Stock Ready for a Re-Rating? Kalkine
StockheadDr Boreham’s Crucible: Late-stage clinical trial curse strikes Cynata Therapeutics
After a double whammy blow, Cynata is “actively reviewing” alternative uses for its Cymerus platform technology. ... Read More The post Dr Boreham’s Crucible: Late-stage clinical trial curse strikes Cynata Therapeutics appeared first on Stockhead.
Cynata Therapeutics (ASX: CYP): Is This Stem-Cell Biotech Stock a High-Risk Opportunity? - Kalkine
Cynata Therapeutics (ASX: CYP): Is This Stem-Cell Biotech Stock a High-Risk Opportunity? Kalkine
Cynata Therapeutics (ASX:CYP): ASX Biotech Stock Back in the Spotlight After Osteoarthritis Trial Update - Kalkine
Cynata Therapeutics (ASX:CYP): ASX Biotech Stock Back in the Spotlight After Osteoarthritis Trial Update Kalkine
KalkineCynata’s Double Setback: What Happens to the Cymerus Platform Now?
Highlights Cynata’s late-stage osteoarthritis study did not achieve its primary goals despite maintaining a favourable safety profile. A recent graft-versus-host disease trial update also fell short of expectations, prompting a broader platform review. Management is now assessing future pathways for the Cymerus stem cell technology platform. Cynata’s latest clinical setback has intensified focus on the future of the Cymerus platform, with management now reviewing strategic options...
Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review - Stocks Down Under
Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review Stocks Down Under
EU Positive Opinion on CYP-001 Paediatric Investigation Plan
other announcement
Cynata Secures Commitments for $1.5m Placement
capital_raise announcement
March 2026 Quarterly Activity Report & Appendix 4C
other announcement
Cynata hits century mark in phase II aGvHD trial
The 100-day primary evaluation period has been completed for the last participant enrolled in Cynata Therapeutics’ Phase II clinical trial ... Read More The post Cynata hits century mark in phase II aGvHD trial appeared first on Stockhead.
Cynata to Present at 2026 Euroz Hartleys Healthcare Forum
other announcement
December 2025 Quarterly Activity Report and Appendix 4C
other announcement
Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
other announcement
Positive DSMB Review in Phase 1/2 Kidney Transplant Trial
other announcement